Intensity-modulated radiotherapy

Cancer Journal

Volumn 8, Issue 2, 2002, Pages 164-176

  Leibel, Steven A ^a   Fuks, Zvi ^a   Zelefsky, Michael J ^a   Wolden, Suzanne L ^a   Rosenzweig, Kenneth E ^a   Alektiar, Kaled M ^a   Hunt, Margie A ^a   Yorke, Ellen D ^a   Hong, Linda X ^a   Amols, Howard I ^a   Burman, Chandra M ^a   Jackson, Andrew ^a   Mageras, Gikas S ^a   LoSasso, Thomas ^a   Happersett, Laura ^a   Spirou, Spiridon V ^a   Chui, Chen Shou ^a   Ling, C Clifton ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

3D CRT; Dose escalation; IMRT; Intensity modulated radiotherapy; Inverse treatment planning; Nasopharynx cancer; Non small cell lung cancer; Ovarian cancer; Prostate cancer; Three dimensional conformal radiotherapy; Whole abdominal irradiation

Indexed keywords

CISPLATIN;

ABDOMINAL RADIOTHERAPY; ACCURACY; ALGORITHM; BRAIN TUMOR; BREAST CARCINOMA; CANCER; CANCER SURVIVAL; FEMALE GENITAL TRACT TUMOR; HEAD AND NECK CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; NASOPHARYNX CANCER; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE DISTRIBUTION; RADIOSENSITIVITY; RECTUM HEMORRHAGE; REVIEW; SOFT TISSUE CANCER; SPINAL CORD TUMOR; SURVIVAL RATE; THYROID CARCINOMA; TREATMENT PLANNING; ABDOMINAL TUMOR; ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; LUNG TUMOR; MALE; METHODOLOGY; NASOPHARYNX TUMOR; NEOPLASM; PROSTATE TUMOR; RADIATION DOSE;

ABDOMINAL NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASMS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL;

EID: 0036512446     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200203000-00010     Document Type: Review

References (82)

1. Leibel SA, Ling C, Kutcher GJ et al. The biological basis for conformal three-dimensional radiation therapy. Int J Radiat Oncol Biol Phys 1991;21:805-811.
2. Thames HD, Schultheiss TE, Hendry JH et al. Can modest escalations of dose be detected as increased tumor control. Int J Radiat Oncol Biol Phys 1994;22:241-246.
3. Bentzen SM. Radiobiological considerations in the design of clinical trials. Radiother Oncol 1994;32:1-11.
4. Levegrun S, Jackson A, Zelefsky MJ et al. Risk group dependence of dose response for biopsy outcome after three-dimensional conformal radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys (in press).
5. Fuks Z, Leibel SA, Kutcher GE et al. Three dimensional conformal treatment: a new frontier in radiation therapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia: JB Lippincott, 1991:151-172.
6. Munzenrider JE, Pilepich M, Rene-Ferrero JB et al. Use of body scanner in radiotherapy treatment planning. Cancer 1979;40:170-179.
7. Leibel SA, Kutcher GJ, Mohan R et al. Three-dimensional conformal radiation therapy at the Memorial Sloan-Kettering Cancer Center. Semin Radiat Oncol 1992;2:274-289.
8. Withers HR, Taylor JM, Maciejewski B. Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys 1988;14:751-759.
9. Jackson A, Skwarchuk MW, Zelefsky MJ et al. Late rectal bleeding after conformal radiotherapy of prostate cancer (II): volume effects and dose volume histograms. Int J Radiat Oncol Biol Phys 2001;49:685-698.
10. Verhey LJ. Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems. Semin Radiat Oncol 1999;9:78-98.
11. Brahme A. Optimization of stationary andmoving beam radiotherapy techniques. Radiother Oncol 1988;12:129-140.
12. Spirou SV, Chui C-S. Generation of arbitrary fluence profiles by dynamic jaws or multileaf collimators. Med Phys 1994;21:1031-1041.
13. Fraas BA, Kessler ML, McShan DL et al. Optimization and clinical use of multisegment intensity-modulated radiation therapy for high-dose conformal therapy. Semin Radiat Oncol 1999;9:60-77.
14. Carol MP. Peacock: a system for planning and rotational delivery of intensity modulated fields. Int J Imaging Syst Technol 1995;6:56-61.
15. Zelefsky MJ, Fuks Z, Happersett L et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000;55:241-249.
16. Zelefsky MJ, Fuks Z, Hunt M et al. High-dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-881.
17. Pollack A, Zagars GK, Rosen II. Prostate cancer treatment with radiotherapy: maturing methods to minimize morbidity. Semin Oncol 1999;26:150-161.
18. Oh CE, Antes K, Darby M et al. Comparison of 2D conventional, 3D conformal, and intensity modulated treatment planning techniques for patients with prostate cancer with regard to target-dose homogeneity and dose to critical, uninvolved structures. Med Dosim 1999;24:255-263.
19. Nutting CM, Convery DJ, Cosgrove VP et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2000;48:649-656.
20. Teh BS, Mai WY, Uhl BM et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis. Int J Radiat Oncol Biol Phys 2001;49:705-712.
21. Xia P, Pickett B, Vigneault E et al. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 2001;51:244-254.
22. Shu HK, Lee TT, Vigneauly E et al. Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer. Urology 2001;57:102-107.
23. Klein EE, Low DA, Sohn JW et al. Differential dosing of prostate and seminal vesicles using dynamic multileaf collimation. Int J Radiat Oncol Biol Phys 2000;48:1447-1456.
24. Hunt MA, Zelefsky MJ, Wolden S et al. Treatment planning and delivery of intensity modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys 2001;49:623-632.
25. Wolden SL, Zelefsky MJ, Pfister DG et al. Improving radiotherapy for nasopharyngeal carcinoma: a 3D boost is not enough [abstract]. Proc Int Conf Head Neck Cancer 2000;5:15.
26. Butler EB, The BS, Grant WH 3rd et al. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 1999;45:21-32.
27. Kuppersmith RB, Greco SC, The BS et al. Intensity-modulated radiotherapy: first results with this new technology on neoplasms of the head and neck. Ear Nose Throat J 1999;78:228-236.
28. Chao KS, Low DA, Perez CA et al. Intensity-modulated radiation therapy in head and neck cancers: the Mallinckrodt experience. Int J Cancer 2000;90:92-102.
29. Chao KS, Deasy JO, Markman J et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001;49:907-916.
30. Cheng JC, Chao KS, Low D. Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int J Cancer 2001;96:126-131.
31. Eisbruch A, Kim HM, Terrell JE et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:695-704.
32. Dawson LA, Anzai Y, Marsh L et al. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2000;46:1117-1126.
33. Wu Q, Manning M, Schmidt-Ulrich R et al. The potential for sparing parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys 2000;46:195-205.
34. Chao KS, Bosch WR, Mutic S et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171-1182.
35. Nutting CM, Rowbottom CG, Cosgrove VP et al. Optimization of radiotherapy for carcinoma of the parotid gland: a comparison of conventional, three dimensional, and intensity-modulated techniques. Radiother Oncol 2001;60:163-172.
36. Xia P, Fu KK, Wong GW et al. Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol 2000;48:329-337.
37. Sultaneim K, Shu H-K, Xia P et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol 2000;48:711-772.
38. Nutting CM, Convery DJ, Cosgrove VP et al. Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland. Radiother Oncol 2001;60:173-180.
39. Li JG, Williams SS, Goffinet DR et al. Breast conserving radiation therapy using combined electron and intensity-modulated radiotherapy technique. Radiother Oncol 2000;56:65-71.
40. Kestin LL, Sharpe MB, Frazier RC et al. Intensity modulation to improve dose uniformity with tangential breast radiotherapy: initial clinical experience. Int J Radiat Oncol Biol Phys 2000;48:1559-1568.
41. van Asselen B, Raaijmakers CP, Hofman P et al. An improved breast irradiation technique using three-dimensional geometrical information and intensity modulation. Radiother Oncol 2001; 58:341-347.
42. Landau D, Adams EJ, Webb S et al. Cardiac avoidance in breast radiotherapy: a comparison of simple shielding techniques with intensity-modulated radiotherapy. Radiother Oncol 2002;60:247-255.
43. Hong L, Hunt M, Chui C et al. Intensity-modulated tangential beam irradiation of the intact breast. Int J Radiat Oncol Biol Phys 1999;44:1155-1164.
44. Yorke ED, Jackson A, Barban L et al. Advantages of IMRT for dose escalation in radiotherapy of lung cancer [abstract]. Med Phys 2001;28:1291-1292.
45. Giraud P, Rosenzweig KE, Yorke E et al. Can intensity-modulated radiation therapy decrease the risk of esophagitis? Int J Radiat Oncol Biol Phys; in press.
46. Hong L, Alektiar K, Chui C et al. IMRT of large fields: whole abdomen irradiation [abstract]. Int J Radiat Oncol Biol Phys 2001;51[suppl 1]:124-125.
47. Roeske JC, Lujan A, Rotmensch J et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologicmalignancies. Int J Radiat Oncol Biol Phys 2000;48:1613-1621.
48. Portelance L, Chao KS, Grigsby PW et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys 2001;51:261-266.
49. Chan MF, Chui CS, Schupak K et al. The treatment of large extra-skeletal chondrosarcoma of the leg: comparison of IMRT and conformal radiotherapy techniques. J Applied Clin Med Phys 2001;1:3-8.
50. Ling CC, Chui C, Losasso et al. Intensity-modulated radiation therapy. In: DeVita VT, Jr, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:777-787.
51. Ling CC, Burman CM, Chui CS et al. Conformal radiation treatment of prostate cancer using inversely planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys 1996;35:721-730.
52. Burman CM, Chui CS, Kutcher GJ et al. Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997;39:863-873.
53. Spirou SV, Chui C-S. A gradient inverse planning algorithm with dose-volume constraints. Med Phys 1998;25:321-333.
54. Shipley WU, Thames HD, Sandler HM et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999;28:1598-1604.
55. Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, Nx/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999;44:809-819.
56. Crook JM, Bahadur YA, Bociek RG et al. Radiotherapy for localized prostate carcinoma: the correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer 1997;79:328-336.
57. Laverdière J, Gomez JL, Cusan L et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:247-252.
58. Leibel SA, Hanks GE, Kramer S. Patterns of care outcomes studies: results of the national practice in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1984;10:401-409.
59. Perez CA, Devineni VR, Marcial-Vega V et al. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys 1992;23:271-280.
60. Sanguineti G, Geara FB, Garden AS et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys 1997;37:985-996.
61. Lee AW, Law SC, Foo W et al. Nasopharyngeal carcinoma: local control by megavoltage irradiation. Br J Radiol 1993;66:528-536.
62. Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317.
63. Leibel SA, Kutcher GJ, Harrison LB et al. Improved dose distributions for 3D conformal boost treatments in carcinoma of the nasopharynx. Int J Radiat Oncol Biol Phys 1991;20:823-833.
64. Wolden SL, Zelefsky MJ, Hunt MA et al. Failure of a 3D conformal boost to improve radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2001;49:1229-1234.
65. Choi SL, Wolden SL, Pfister DG et al: Ototoxicity following combined modality therapy for nasopharyngeal carcinoma [abstract]. Int J Radiat Oncol Biol Phys 2000;48 [suppl]:261.
66. Dillman RO, Herndon J, Seagren SL et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215.
67. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
68. Arriagada R, Chevalier T, Quoix E et al. ASTRO plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys 1991;20:1183-1190.
69. Emami B. Three-dimensional conformal radiation therapy in bronchogenic carcinoma. Semin Radiat Oncol 1996;6:92-97.
70. Perez CA, Pajak TF, Rubin P. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Cancer 1987;59:1874-1881.
71. Hayman JA, Martel MK, Ten Haken RK et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001;19:127-136.
72. Rosenzweig KE, Sim S, Mychalczak B et al. Elective nodal irradiation in the treatment of non-small cell lung cancer with three-dimensional conformal radiation therapy (3D-CRT). Int J Radiat Oncol Biol Phys 2001;50:681-685.
73. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
74. Redman CW, Mould J, Warwick J et al. The West Midlands epithelial ovarian cancer adjuvant therapy trial. Clin Oncol 1993;5:1-5.
75. Cardenes H, Randall ME. Integrating radiation therapy in the curative management of ovarian cancer: current issues and future directions. Semin Radiat Oncol 2000;10:61-70.
76. Ling CC, Humm J, Larson S et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-560.
77. 3) spatial resolution. Radiology 1996;198:795-805.
78. Wefer AE, Hricak H, Vigneron DB et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000;164:400-404.
79. LoSasso T, Chui CS, Ling CC. Physical and dosimetric aspects of a multileaf collimation system used in the dynamic mode for implementing intensity modulated radiotherapy. Med Phys 1998;25:1919-1927.
80. Kutcher GJ, Mageras GS, Leibel SA. Control, correction, and modeling of setup errors and organ motion. Semin Radiat Oncol 1995;5:134-145.
81. Jaffray DA, Yan D, Wong JW. Managing geometric uncertainty in conformal intensity-modulated radiation therapy. Semin Radiat Oncol 1999;9:4-19.
82. Verellen D, Vanhavere F. Risk assessment of radiation-induced malignancies based on whole-body equivalent dose estimates for IMRT treatment in the head and neck region. Radiother Oncol 1999;53:199-203.